Palvella Therapeutics PVLA
$142.85 −$2.92 (-2.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $142.85 0.00%
Open$143.10
Prev close$145.77
Day range$142.22 – $148.69
Volume192.7K
Market cap$2.09B
P/E (TTM)–
Dividend yield–
PVLA Stock News
Headlines matching Palvella Therapeutics or the PVLA ticker, most recent first.
- Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240
- Palvella Therapeutics(PVLA.US) Director Sells US$4.17 Million in Common Stock
- Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 4.14 Million in Common Stocks
- Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
- H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270
- Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207
- A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267
- Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210
- LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225
- BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215
- TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267 Positive
- Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)
- CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227
- Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250
- Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205
No comments yet — be the first to weigh in on PVLA.
Sign in to join the discussion.